Molbio Diagnostics reappoints K.S. Kamalakara & Co as cost auditors for FY27

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Molbio Diagnostics reappointed M/s K. S. Kamalakara & Co as cost auditors for FY27
  • The firm is based in Bengaluru and holds Firm Registration No. 000296
  • Board approved the reappointment on September 25, 2026
  • CMA K. S. Kamalakara leads the firm with over two decades of experience
powered bylight_fuzz_icon
51868805

*this image is generated using AI for illustrative purposes only.

Molbio Diagnostics Limited has reappointed M/s K. S. Kamalakara & Co, Cost Accountants, as its cost auditors for the financial year 2026-27. The decision was taken by the Board of Directors during a meeting held on September 25, 2026.

The reappointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The firm, registered with Firm Registration No. 000296, is a peer-reviewed entity based in Bengaluru, India.

Auditor Profile and Expertise

M/s K. S. Kamalakara & Co is described in the disclosure as a prominent and professionally managed firm of Cost Accountants. The firm specializes in a range of compliance and accounting services, including:

  • GST and indirect taxation
  • Cost accounting and cost audits
  • Financial accounting
  • Import-export policy and customs
  • Export benefit claims and FEMA compliances
  • Litigation support and project report preparation

The firm is led by its founding partner, CMA K. S. Kamalakara (M.Com., FCMA). He is a Fellow Cost Accountant with over two decades of experience in cost records, audits, indirect taxation, and corporate litigation matters.

Disclosure Details

The company provided the following details regarding the appointment in its regulatory filing:

Particulars Details
Reason for change Re-appointment of M/s. Kamalakara & Co as cost auditors
Date of re-appointment September 25, 2026
Term of appointment Financial year 2026-27
Firm Registration No. 000296

The Board meeting commenced at 11:26 am and concluded at 11:35 am. The intimation was also made available on the company's website in compliance with Regulation 46 of the SEBI LODR Regulations, 2015.

Historical Stock Returns for Molbio Diagnostics

1 Day5 Days1 Month6 Months1 Year5 Years
+0.67%-2.39%+4.61%+55.46%+55.46%+55.46%

How might the reappointment of the same cost auditor impact Molbio Diagnostics' long-term cost optimization strategies for FY2026-27?

What are the potential implications of this compliance decision on investor confidence regarding Molbio's corporate governance standards?

Could the continuity of K. S. Kamalakara & Co influence Molbio's upcoming capital expenditure plans or product pricing structures?

Molbio Diagnostics shares worth ₹365.64 crore flag large-trade signal

scanx
Reviewed by
Ritika DScanX News Team
Key Highlights
  • Approximately 27,80,549 Molbio Diagnostics shares changed hands on BSE, flagged as a large-trade signal
  • The shares traded at ₹1,315.00 per share, for a combined value of ₹365.64 crore
  • This is a real-time signal from a trade-scanning system, not a confirmed exchange-level event
  • Buyer, seller, and client identities are not known; official disclosures are made by the exchange only after market close
powered bylight_fuzz_icon
51686598

*this image is generated using AI for illustrative purposes only.

Molbio Diagnostics shares worth ₹365.64 crore were flagged by a real-time trade-scanning system after approximately 27,80,549 shares changed hands on BSE at a price of ₹1,315.00 per share.

This is a real-time large-trade signal, not a confirmed block or bulk deal. NSE/BSE publish official block and bulk deal reports only after market close — this trade may or may not appear there.

Large-trade signal details

The following table summarises the parameters of the flagged activity:

Parameter Details
Exchange BSE
Approximate shares ~27,80,549
Price per share ₹1,315.00
Approximate value ₹365.64 crore

The signal reflects a cluster of trades in Molbio Diagnostics shares printed within a short window at or near ₹1,315.00, for a combined value of ₹365.64 crore. The activity was flagged by the system on account of its size and speed and does not, by itself, constitute a confirmed exchange-level event. No buyer, seller, broker, or client identity is known at this stage, as such disclosures are made only by the exchange after market close.


What this is, and isn't: this reflects trade-level activity — a cluster of trades in the stock above, printed within a short window at or near the quoted price, for a combined value as stated. It is generated by our real-time trade-scanning system and is not, by itself, evidence of a block or bulk deal.

A block deal has to be executed in the exchange's dedicated window (8:45–9:00am or 2:05–2:20pm), within a set price band, and above the current minimum order size (₹25 crore). A bulk deal is when one client's total trading in a stock crosses 0.5% of its equity in a single day — confirmed only once every trade that client made is added up.

Both are published by NSE/BSE after trading hours end, typically after 3:30pm — never before. If this trade qualifies as either, it will appear in the exchange's own report later today, not here first.

Historical Stock Returns for Molbio Diagnostics

1 Day5 Days1 Month6 Months1 Year5 Years
+0.67%-2.39%+4.61%+55.46%+55.46%+55.46%
Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

Will the official exchange disclosures later today confirm this activity as a bulk deal or block deal, and who are the identified counterparties?

How might the confirmation of a ₹365 crore institutional exit impact Molbio Diagnostics' share price volatility in the immediate trading sessions?

Does this large-scale trade signal a broader trend of institutional de-risking from the Indian diagnostics sector amidst current market conditions?

More News on Molbio Diagnostics

1 Year Returns:+55.46%